Board meeting for results: 28 Oct 2026 (NSE event calendar; dates can change) · all upcoming results
Key numbers
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 107 companies in Specialty Chemicals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹115 cr vs borrowings ₹148 cr (FY26): borrowings are higher by ₹34 cr.
- Operating profit covered interest 30.9x in the last 12 months.
- Net loss in 1 of the last 4 quarters.
- Other income was 22% of net profit in the last 12 months.
- No dividend in the last 1 financial years.
- Price ₹1,022.40 on 2026-10-27: -25.8% from the 52-week high, +95.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Quarterly results
| ₹ cr | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 163 | 172 | 182 | 158 |
| EBITDA | 55 | 60 | 63 | 55 |
| OPM % | 34.1% | 34.8% | 34.3% | 34.7% |
| Other income | 10 | 7 | 6 | 5 |
| Net profit | 46 | -2 | 49 | 41 |
| EPS (₹) | 4.20 | 4.29 | 4.38 | 3.59 |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY26 | TTM |
|---|---|---|
| Revenue | 642 | 676 |
| EBITDA | 222 | 233 |
| Net profit | 173 | 133 |
| EPS (₹) | 15.50 | 16.46 |
| Dividend / share (₹) | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY26 |
|---|---|
| Shareholders' equity | 883 |
| Borrowings | 148 |
| Cash & equivalents | 115 |
| Total assets | 1,175 |
| Fixed assets | 224 |
| Capital work in progress | 178 |
| Investments | 0 |
| Receivables | 228 |
| Inventory | 216 |
| Payables | 68 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY26 |
|---|---|
| Cash from operations | 70 |
| Cash from investing | -327 |
| Cash from financing | 247 |
| Capex | 118 |
| Free cash flow | -49 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY26 |
|---|---|
| ROE % | 19.6% |
| ROCE % | 22.8% |
| Debtor days | 129 |
| Inventory days | 347 |
| Payable days | 110 |
| Cash conversion cycle (days) | 366 |
| Working capital days | 240 |
Shareholding
| Holder (% of shares) | 2025-11-31 | 2026-02-31 | May 2026 | Aug 2026 | 2026-11-31 | Change since 2025-11-31 |
|---|---|---|---|---|---|---|
| No. of shareholders | – | – | – | – | – | – |
| Promoter group | % |
|---|---|
| Riva Resources Private Limited | 40.35% |
| Bhayani Sujit Jaysukh | 21.16% |
| Sujeet Jaysukh Bhayani Huf | 5.72% |
| Avani Sujeet Bhayani | 4.47% |
| Shanil Sujit Bhayani | 4.45% |
| Jaysukh Jayantilal Bhayani | 0.00% |
| Dipen Jaysukh Bhayani | 0.00% |
| Urvir Jaysukh Bhayani | 0.00% |
| Rhea Sujit Bhayani | 0.00% |
| Anjana Rajendrabhai Patel | 0.00% |
| Rajendra Chunilal Patel | 0.00% |
| Vidhi Shanil Bhayani | 0.00% |
| Inaraa Shanil Bhayani | 0.00% |
| Alka Pravinchandra Kotak | 0.00% |
| Pravinchandra Talakshibhai Kotak | 0.00% |
| Public holders above 1% | % |
|---|---|
| Sbi Healthcare Opportunities Fund | 2.85% |
| Nuvama Crossover Opportunities Fund - Series Iii B | 2.14% |
| Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund | 1.81% |
| Mukul Mahavir Agrawal | 1.33% |
| Nuvama Crossover Opportunities Fund - Series Iii | 1.11% |
| Nuvama Crossover Opportunities Fund - Series Iii A | 1.08% |
40,465 shareholders. Pledged: – of promoter shares.
From the company's quarterly shareholding-pattern filings on the exchange (NSE/BSE), latest as of Sep 2026. "pts" = percentage points; the number of shareholders is as filed by the company. No filing on our file for 2025-11-31, 2026-02-31, May 2026, Aug 2026, 2026-11-31 (shown as –).
Peers in Specialty Chemicals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| PIDILITIND | ₹1,47,581 cr | 55.7x | 13.6x | 25.7% | 33.4% | 24.5% | +7.4% | 1.03% |
| FLUOROCHEM | ₹46,593 cr | 76.1x | 5.9x | 8.1% | 10.0% | 25.6% | -4.2% | 0.07% |
| NAVINFLUOR | ₹42,343 cr | 53.5x | 10.7x | 23.9% | 22.2% | 33.7% | +16.8% | 0.17% |
| AETHER | ₹20,403 cr | 86.5x | 8.3x | 10.1% | 11.4% | 30.9% | +21.2% | – |
| DEEPAKNTR | ₹19,526 cr | 24.9x | 3.4x | 14.0% | 15.3% | 15.4% | -0.4% | 0.52% |
| ATUL | ₹15,937 cr | 20.0x | 2.6x | 11.9% | 16.9% | 17.9% | +7.9% | 0.47% |
| AARTIIND | ₹15,804 cr | 29.8x | 2.7x | 9.2% | 8.0% | 14.9% | +7.8% | 0.23% |
| FINEORG | ₹15,660 cr | 35.7x | 5.9x | 17.7% | 21.3% | 21.7% | -7.8% | 0.22% |
| PRIVISCL | ₹13,791 cr | 39.4x | 9.8x | 27.6% | 22.6% | 24.9% | +16.8% | 0.14% |
| SUDEEPPHRM | ₹11,548 cr | 62.1x | 13.1x | 15.1% | 23.9% | 34.5% | – | – |
Business segments (FY26)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| Pharmaceutical, Food and Nutrition | ₹363 cr | 55.7% | ₹114 cr | 31.3% |
| Speciality Ingredients | ₹280 cr | 43.0% | ₹94 cr | 33.5% |
| Inter Segment Revenue | ₹8 cr | 1.3% | ₹0 cr | 0.0% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-07-23 | Dividend | Dividend - Rs 1.50 Per Share |
Latest filings
- Press Release
Sudeep Pharma Limited has informed the Exchange regarding a press release dated October 26, 2026, titled "Press Release - FDA approval for the new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat, ".
- Analysts/Institutional Investor Meet/Con. Call Updates
Sudeep Pharma Limited has informed the Exchange about Schedule of meet
- Change in Management
Sudeep Pharma Limited has informed the Exchange about change in Management
- Analysts/Institutional Investor Meet/Con. Call Updates
Sudeep Pharma Limited has informed the Exchange about Schedule of meet
- Analysts/Institutional Investor Meet/Con. Call Updates
Sudeep Pharma Limited has informed the Exchange about Schedule of meet
- Analysts/Institutional Investor Meet/Con. Call Updates
Sudeep Pharma Limited has informed the Exchange about Schedule of meet
- Analysts/Institutional Investor Meet/Con. Call Updates
Sudeep Pharma Limited has informed the Exchange about Transcript
- Updates
Sudeep Pharma Limited has informed the Exchange regarding 'General Update'.
- Analysts/Institutional Investor Meet/Con. Call Updates
Sudeep Pharma Limited has informed the Exchange about Link of Recording
- Shareholders meeting
Sudeep Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 04, 2026. Further, the company has informed the Exchange regarding voting results.
- Investor Presentation
Sudeep Pharma Limited has informed the Exchange about Investor Presentation
- Investor Presentation
Sudeep Pharma Limited has informed the Exchange about Investor Presentation
- Outcome of Board Meeting
Sudeep Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
- Shareholders meeting
Sudeep Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 04, 2026
Filed by the company on NSE in the last 3 months (routine notices left out). The text under each title is a short extract of the company's own filing; the link opens the full original file on the NSE website. Fetched 27 Oct 2026.
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Commodities |
| Industry | Specialty Chemicals |
| Sub-industry | Specialty Chemicals |
| Symbol | SUDEEPPHRM |
| BSE code | 544619 |
| ISIN | INE0QPI01025 |
| Face value | ₹1.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-27.